Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-18-003338
Filing Date
2018-04-26
Accepted
2018-04-26 16:15:22
Documents
4
Period of Report
2018-06-07
Effectiveness Date
2018-04-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A def14a.htm DEF 14A 845257
2 GRAPHIC def14ag001.jpg GRAPHIC 4750
3 GRAPHIC def14ag002.gif GRAPHIC 59235
4 GRAPHIC def14ag003.gif GRAPHIC 40253
  Complete submission text file 0001558370-18-003338.txt   990256
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37581 | Film No.: 18778730
SIC: 2834 Pharmaceutical Preparations